Taysha Gene Therapies Inc (NAS:TSHA)
$ 2.05 0.03 (1.49%) Market Cap: 420.13 Mil Enterprise Value: 298.96 Mil PE Ratio: 0 PB Ratio: 3.80 GF Score: 27/100
Back to the Transcripts List

Q2 2024 Taysha Gene Therapies Inc Earnings Call Transcript

Aug 12, 2024 / 12:30PM GMT
Release Date Price: $2.04 (-2.39%)

Key Points

Positve
  • Encouraging safety and efficacy data from the low-dose cohort in both REVEAL Phase 1/2 trials.
  • Initiation of the high-dose cohort and expansion of the pediatric trial into Canada.
  • Strengthened balance sheet with $76.8 million in net proceeds from a public follow-on offering.
  • TSHA-102 demonstrated a well-tolerated safety profile with no serious adverse events or dose-limiting toxicities.
  • Potential transformative therapeutic option for Rett syndrome, addressing a significant unmet medical need.
Negative
  • Dependence on strategic alliances and third-party relationships for development.
  • Uncertainties related to the timing and results of clinical trials and regulatory interactions.
  • High costs associated with research and development activities.
  • Complexity in treating Rett syndrome due to the heterogeneous nature of the disease.
  • Potential challenges in demonstrating a clear dose-response relationship in clinical trials.
Operator

Greetings, and welcome to the Taysha Gene Therapies second-quarter 2024 earnings call. (Operator Instructions)

As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Hayleigh Collins, Director and Head of Corporate Communications and Investor Relations. Thank you. You may begin.

Hayleigh Collins
Taysha Gene Therapies Inc - Director, Head of Corporate Communications and Investor Relations

Thank you. Good morning, and welcome to Taysha's second-quarter 2024 financial results and corporate update conference call. Earlier today, Taysha issued a press release announcing financial results for the second quarter ended June 30, 2024. A copy of this press release is available on the company's website and through our SEC filings.

Joining me on today's call are Sean Nolan, Taysha's CEO, Sukumar Nagendran, President and Head of R&D, and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks.

Please note that on today's call, we

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.